Sanofi Genzyme
http://www.genzyme.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanofi Genzyme
Pharma Versus Hospitals: 340B Battle Continues
Exploring the continued controversy around the 340B US federal drug discount program. As the story moves into 2022, key questions remain unanswered.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
Seventeen And Counting – Bumper Crop Of New EU Filings
Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.
Sanofi ‘Strongly Disagrees’ With EMA Rejection Of NAS Status For Nexviadyme
Sanofi argues that the European Medicines Agency applies a narrow interpretation of its new active substance principles which is not appropriate for biological therapies, and that the regulator fails to consider the challenges of conducting clinical research in rare diseases.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- AnorMED
- Bioenvision
- ILEX Oncology, Inc.
- Sangstat Medical Corporation
- Genzyme Corporation